Business Wire

MA-HOLOGIC

21.9.2021 13:02:08 CEST | Business Wire | Press release

Share
Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index , the world’s most comprehensive, globally comparative survey about women’s health.

Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls.

Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scored more than 69. Country and territory rankings can be found here . Notably, 40% of those surveyed – equating to about a billion women and girls – said they had not talked to a healthcare professional in the last year, while approximately 60% – about 1.5 billion – were not tested for four common diseases that affect women’s health.

“Women’s health is the cornerstone of families, communities, societies and economies,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “As a leader in the early detection, diagnosis and treatment of women’s health issues, we know firsthand that measurement is the key to improvement. We saw a clear need for more robust, quality data to track and measure women’s health on a global level — particularly as COVID-19 has worsened longstanding healthcare disparities. The Hologic Global Women’s Health Index is the first global survey that uniquely draws from women’s perspectives to determine priorities.”

The Hologic Global Women’s Health Index provides an actionable, science-backed data roadmap for improving life expectancy and quality of life for women and girls worldwide. To help countries and territories determine a strategy for ensuring a healthy future for women, the Index identifies five dimensions of women’s health that explain more than 80% of women’s average life expectancy at birth: Preventive Care, Opinions of Health and Safety, Emotional Health, Individual Health and Basic Needs. In the Index, countries and territories are ranked across each of these five dimensions, then those scores are combined to create an overall ranking. Positive improvements on any of the five dimensions could potentially help women live healthier, longer lives.

“In line with critical UN Sustainable Development Goals and the UN General Assembly theme of ‘Building Resilience Through Hope,’ we urge global healthcare and government leaders to use this data and the five dimensions to guide the development of actionable and measurable plans and investments that prioritize women’s health,” said MacMillan.

While the Hologic Global Women’s Health Index was initiated before COVID-19 affected the world, the pandemic and its effects on the already precarious state of women’s healthcare — including postponed or canceled preventive care examinations, increased poverty levels, and insufficient access to medical facilities and education — have created a more urgent need for world leaders and policymakers to prioritize women’s health.

“The COVID-19 pandemic has both exacerbated and shed light on longstanding gaps in access and quality of healthcare,” said Vipula Gandhi, Senior Managing Partner at Gallup. “The Index provides a baseline from which we can measure the state of women’s health globally. We hope this study will serve as a call to action for world leaders and policymakers as they navigate the global recovery.”

Hologic is committed to conducting the Global Women’s Health Index on a regular basis so world leaders can take action. This commitment builds on Hologic’s more than 30 years of championing women’s health around the world through its products for breast and cervical cancer screening, infectious disease detection, and gynecologic surgery, and its partnerships with numerous global initiatives promoting better access to healthcare .

Country and Territory Rankings Influenced by Disparities in Income and Health Systems

In this first year of the Hologic Global Women’s Health Index, no single country or territory scored more than 69 out of 100. Generally, most countries and territories that lead the world on the Index also lead the world in how much of their wealth they invest back into their health systems, including Austria, Switzerland and Norway. Overall, while women in high-income countries and territories were only 17% of the women surveyed in the Index, they collectively have at least a seven-point lead on the Index over all other women globally.

Conversely, the countries and territories with the lowest scores on the Hologic Global Women’s Health Index all share high income inequality and weak or destabilized infrastructure for healthcare. The countries and territories with the lowest scores on the Index are a mix of mostly low- and lower-middle income economies. Few countries and territories in this group score well in meeting women’s basic needs and are significantly lagging in the Preventive Care dimension.

Universal Challenges Around Preventive Care

“Preventive measures are a crucial first step to combating diseases and infections affecting life expectancy and fertility in women,” said Susan Harvey, MD, Vice-President of Global Medical Affairs, Hologic. “Failing to ensure women get routine testing for cancers, sexually transmitted diseases and infections, and cardiometabolic diseases can lead to larger complications that would otherwise be preventable if monitored or treated early.”

While international testing standards differ, the Hologic Global Women’s Health Index found that within the past 12 months, more than 1.5 billion women were not tested for any of four critical diseases for women: cancer, diabetes, high blood pressure and sexually transmitted diseases/infections (STDs/STIs).

  • Just 12% of women worldwide reported being screened for any type of cancer.
  • Globally, only about one in five (19%) women reported being screened for diabetes, the sixth leading cause of death for women around the world. In countries and territories with high obesity rates such as the United States, one in three women (34%) reported being tested.
  • On average, only one in three women (33%) worldwide had their blood pressure tested despite heart disease being the leading cause of death globally for women and men.
  • Fewer than one in nine women (11%) reported being tested for STDs/STIs, which are risk factors for further health issues like HIV, cancer and infertility. 

A Holistic Approach to Women’s Health

Collectively, the world in 2020 felt the worst it has in 15 years. Global experiences of worry, stress, sadness and anger continued to rise and set new records. About four in ten women said they experienced worry (40%) and stress (38%) during a lot of the previous day.

Many women surveyed also expressed concerns about their safety and ability to meet basic needs like food and shelter.

  • Two in three women (66%) — which translates into roughly 1.7 billion women — cited domestic violence as a widespread problem in their country.
  • Nearly one in three (32%) — more than 800 million women — said they are afraid to walk alone at night.
  • More than one in three (34%) — nearly 900 million women — said they struggled to afford food in the past year.
  • Nearly three in ten (29%) — or nearly 700 million women — said they struggled to afford adequate housing for themselves and their families.

For more information about the Hologic Global Women’s Health Index and year one findings, please visit hologic.womenshealthindex.com .

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .

Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries and territories.

About the Gallup World Poll

The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries and territories. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people's lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.

Forward Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.

SOURCE : Hologic, Inc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye